Yes, Wegovy now comes as a pill. The name did not change, which is why it is easy to miss: the same brand is labelled as both a once-weekly injection and a once-daily tablet.
The tablet is semaglutide — the identical molecule to the injection — in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, and it is approved for weight management, not only for diabetes.
That last point is what separates it from Rybelsus, and it is the distinction most people searching for an oral GLP-1 are actually looking for.
The dosing schedule
One tablet daily, stepped up every 30 days:
| Days | Dose |
|---|---|
| 1–30 | 1.5 mg once daily |
| 31–60 | 4 mg once daily |
| 61–90 | 9 mg once daily |
| 91 onward | 25 mg once daily (maintenance) |
Reaching the maintenance dose takes about three months. That is a slower ramp than most people expect, and it is deliberate — the same gradual titration the injection uses, for the same reason: to let the gut adapt.
If you miss a day, the label is unambiguous: skip the missed dose and take the next one the following day. Do not double up.
The administration rule, which is not optional
This is the part worth reading twice, because it is where the tablet differs from every other GLP-1 and where it quietly goes wrong.
From the labelling: "Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water."
Then: "After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications."
And: "Swallow tablets whole. Do not split, crush, chew or dissolve in any solution."
Read as a checklist:
- Empty stomach. Morning, before anything.
- Water only, and no more than four ounces — about half a mug. Not coffee, not juice, not tea.
- Whole. No splitting or crushing, even if swallowing tablets is difficult.
- Thirty minutes of nothing afterwards — no food, no other drinks, and no other tablets.
Why it matters this much: peptides are badly absorbed through the gut, which is the reason semaglutide was an injection first. An oral version only works because of an absorption enhancer that needs specific stomach conditions. Food, other liquids, and even a large volume of water change those conditions.
The failure mode is silent. Taking it with breakfast does not cause a warning or an obvious symptom — it means less drug crosses into the bloodstream. You would experience that as the drug not working very well, and reasonably conclude the drug does not work very well.
If you already take a morning thyroid tablet, the two compete for the same empty stomach. That is a conversation to have with your prescriber before starting, not after.
What it costs
This is where the tablet is genuinely surprising, and the figures come from the manufacturer's own self-pay channel rather than a list price:
| Route | Monthly cost | Who it is for |
|---|---|---|
| Self-pay, tablets (1.5 mg or 4 mg) | From $149 | Cash payers |
| Commercial insurance + savings offer | As little as $25 | Private or employer plans; savings capped at $100/month |
| Medicare GLP-1 Bridge programme | $50 | Eligible Medicare patients |
| Self-pay, injection (new patients) | From $199 for 2 months | Comparison point |
| Wegovy HD (7.2 mg injection) | From $399 | Comparison point |
At $149 a month the tablet is currently the cheapest branded GLP-1 in the United States — below the Wegovy injection's promotional price and well below LillyDirect's Zepbound self-pay tier. For anyone who has been pricing compounded semaglutide against branded, that comparison has changed materially.
That $149 is corroborated from a second channel: TrumpRx, the federal price-aggregation site, lists the Wegovy tablet at $149 a month against a $1,349 list price, alongside the Wegovy pen at $199, Ozempic at $199 and Zepbound at $299. Two independent listings at the same figure is a firmer footing than a single promotional page.
Two caveats on those numbers, because both are dated offers rather than permanent pricing: the 4 mg self-pay price is stated as available only until 31 August 2026, and the injection's $199 new-patient price runs to 31 December 2026. Prices in this market move quarterly. Confirm before you plan around them, and see GLP-1 costs without insurance for the full route map.
One correction worth making, because the savings-card rules are widely misstated: government-insured patients are not simply excluded. They cannot use the commercial savings card, but they can pay the self-pay price outside their insurance entirely — and there is now a separate Medicare route at $50 a month. See does Medicare cover GLP-1.
What it is approved for
The tablet carries two indications in adults:
- Weight reduction and maintenance in obesity, or in overweight with at least one weight-related condition.
- Reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease plus obesity or overweight.
Two things it is not approved for, both of which the injection has and the tablet does not: paediatric use, and the MASH liver indication. If either is the reason for the prescription, the tablet is not the equivalent product.
Wegovy tablets vs Rybelsus
Both are oral semaglutide from the same manufacturer, which is exactly why they get confused.
| Wegovy tablets | Rybelsus | |
|---|---|---|
| Approved for | Weight management + CV risk | Type 2 diabetes |
| Strengths | 1.5, 4, 9, 25 mg | 3, 7, 14 mg |
| Maintenance dose | 25 mg | 14 mg |
| Administration | Identical: empty stomach, morning, ≤4 oz water, wait 30 minutes | |
The practical consequence is a coverage one. An insurer that will not cover weight-loss drugs may cover Rybelsus for diabetes and refuse Wegovy tablets for weight, even though both are oral semaglutide. See Rybelsus for weight loss for where that leaves people who want the higher dose.
Side effects and the boxed warning
Wegovy tablets carry the same boxed warning as every semaglutide product: in rodents, semaglutide caused dose-dependent thyroid C-cell tumours at clinically relevant exposures. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone who has had a serious hypersensitivity reaction to semaglutide.
On everyday side effects, the label states that the types and frequency of common adverse reactions were similar to the injection — nausea, diarrhoea, vomiting, constipation and abdominal pain dominate, worst during titration. It does not publish separate percentages for the tablet, so neither will we.
Two figures it does give for the tablet trial: dysesthesia — altered or uncomfortable sensation — in 5% of treated patients against 0% on placebo, and severe gastrointestinal reactions in 2% against 0%. Dysesthesia is not a side effect most people associate with this class, and it is worth recognising if it appears. See the GLP-1 side effects timeline for what to expect and when.
How much weight does the pill actually take off?
Here we have to be straight with you: the label does not publish a weight-loss percentage for the tablet. It references the tablet trial and reports safety findings from it, but no efficacy figure appears in the labelling we read.
What is documented is the injection: roughly 14.9% mean body-weight loss over 68 weeks in STEP-1 at 2.4 mg weekly. The tablet is the same molecule and reaches a maintenance dose intended to deliver comparable exposure — but "intended to" is not a result, and we are not going to present one as though it were.
For context on where any of this sits against the alternatives, see GLP-1 weight loss results by drug.
Is the pill better than the injection?
Different, not better, and the trade is legible.
The tablet asks for daily discipline in exchange for no needles. Thirty minutes of an empty stomach, every morning, indefinitely — against one injection a week and no rules about breakfast. For someone with a genuine needle aversion, that is an easy trade. For someone with a chaotic morning, it is not, and the cost of getting it wrong is absorbed dose rather than a missed appointment.
Where the tablet clearly wins today is price. $149 a month self-pay against $199 for the injection, and against $349–$399 for branded tirzepatide, is a real gap.
This article is general information, not medical advice. Dosing, administration, indications, contraindications and the adverse-reaction figures quoted here were read from the Wegovy labelling on DailyMed on 5 August 2026; prices were read from the manufacturer's self-pay and savings pages the same day and are explicitly time-limited offers. Labels are revised and prices in this market move quarterly — confirm both before acting. Any decision to start, switch or stop a GLP-1 belongs with a qualified clinician who knows your history.
Scientific References
3 sources- 1
Novo Nordisk Pharmaceutical Industries, LP
WEGOVY (semaglutide) injection, solution; WEGOVY (semaglutide) tablet — prescribing information
DailyMed, U.S. National Library of Medicine · 2026
NIH - 2
Novo Nordisk
Wegovy savings and self-pay pricing
NovoCare · 2026
- 90
U.S. Government
TrumpRx — manufacturer cash prices for prescription medicines
trumprx.gov · 2026
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
What doses does the Wegovy pill come in?
1.5 mg, 4 mg, 9 mg and 25 mg, taken once daily. You step up one strength every 30 days — 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg as the maintenance dose from day 91 onward. Reaching maintenance takes about three months.
How do you take Wegovy tablets?
On an empty stomach in the morning, with water only and no more than 4 ounces of it. Swallow the tablet whole — do not split, crush, chew or dissolve it. Then wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. This is not a nicety: oral semaglutide is poorly absorbed and depends on those stomach conditions, so taking it with coffee or breakfast means absorbing less drug, with no symptom to tell you it happened.
How much does the Wegovy pill cost?
The manufacturer's self-pay price starts at $149 a month for the 1.5 mg or 4 mg doses, which currently makes it the cheapest branded GLP-1 in the United States. With commercial insurance and the savings offer it can come down to $25 a month, with savings capped at $100 a month, and eligible Medicare patients have a separate $50 monthly route. The 4 mg self-pay price is stated as available only until 31 August 2026, so confirm current figures before planning around them.
Is the Wegovy pill the same as Rybelsus?
Same molecule, different product. Both are oral semaglutide from Novo Nordisk, but Rybelsus is approved for type 2 diabetes at 3, 7 and 14 mg, while Wegovy tablets are approved for weight management and cardiovascular risk reduction at 1.5, 4, 9 and 25 mg. The administration rules are identical. The practical difference is coverage: an insurer that refuses weight-loss drugs may cover Rybelsus and decline Wegovy tablets.
What if I miss a dose of Wegovy tablets?
Skip it and take the next dose the following day. The label is explicit about this — do not double up to catch up.
How much weight do you lose on the Wegovy pill?
The labelling does not publish a weight-loss percentage for the tablet. It references the tablet trial and reports safety findings from it, but no efficacy figure appears. What is documented is the injection at 2.4 mg weekly: roughly 14.9% mean body-weight loss over 68 weeks in STEP-1. The tablet is the same molecule at a maintenance dose intended to give comparable exposure, but that is a design intention rather than a published result.
What are the side effects of the Wegovy pill?
The label states the types and frequency of common adverse reactions were similar to the injection — nausea, diarrhoea, vomiting, constipation and abdominal pain, worst during titration — without publishing separate percentages for the tablet. Two tablet-trial figures it does give are dysesthesia, meaning altered or uncomfortable sensation, in 5% of treated patients against 0% on placebo, and severe gastrointestinal reactions in 2% against 0%. It also carries semaglutide's boxed warning for thyroid C-cell tumours and is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.